Scottish Equity Partners (SEP) said it has made “one of the most successful exits for a UK venture capital backed business in the emerging digital health market” with the sale of Exco InTouch to ERT.
SEP said Exco InTouch is a “provider of patient engagement, data capture and digital health solutions for the clinical research and healthcare industry” and ERT is a provider of “patient data collection solutions for use in clinical drug development.”
SEP first invested in Exco InTouch in 2011 and is the company’s largest shareholder.
Jan Rutherford, partner at SEP and non-executive director of Exco InTouchsaid: “Exco InTouch has been widely recognised as one of the fastest growing technology companies in the UK, quadrupling its turnover over the last three years.
“SEP has actively supported the company in driving technological innovation for both clinical trial and digital health programs and expanding its partnerships with pharma companies in both the US and Europe.
“The acquisition by ERT is a great strategic fit, opening up further opportunities for progression and we wish the talented team continued success with this exciting next stage of growth.”
SEP said the combined organisation will provide the biopharmaceutical industry “with the most advanced and comprehensive choice for electronic clinical outcome assessments, patient engagement and digital health and will help clients minimise risks, run safer and more efficient studies, and get new clinical treatments to patients more quickly.”
ERT CEO James Corrigan said: “Exco InTouch has a great history of innovation, and since its inception has made significant contributions to the eClinical landscape.
“We are delighted to welcome them to the ERT team, and look forward to working together to deliver market-leading offerings that solve our clients’ most complex challenges.”